As of 31 December 2018, the Group employed 366 staff, including 90 staff in the PRC R&D department, 97 staff in the PRC production department, 125 staff in the PRC commercial office and 12 staff in the Hong Kong headquarters. In addition to the full-time employees in the PRC sales offices, the Group has 167 regional distributors.
The Board of directors of the Company (the “Board”) is comprised of a Chairman, a vice-chairman and 4 Non-executive Directors.
Uni-Bio Science currently commercialises its products in Mainland China, with presence in all 22 provinces, four municipalities and five autonomous regions. Domestic sales currently account for 100% of our revenue from pharmaceutical products and the Company aim to expand into the international market in the future.
The Company focuses on the research and development of innovative treatments in diabetes (including other metabolic diseases), ophthalmology and dermatology , with priority in developing Class I & VII prescription drugs. Uni-Bio Science’s Class I prescription new drugs in development include Uni-E4(2nd Generation Injection) for treating of Type 2 diabetes, and the Class VII prescription new drug includes Uni-PTH used for treating osteoporosis.
GeneTime® (recombinant human epidermal growth factor, an external-use spray) can be applied for burn wounds (including superficial or deep second-degree burns), small residual wounds, different kinds of chronic ulcer wounds (including vascular, radiation, diabetes ulcers), surgical wounds and new skin donor site wounds etc. At present, it is the only epidermal growth factor spray in China. Its aseptic packaging allows easy and convenient usage, reducing the possible repercussions from misuse.
GeneSoft® (recombinant human epidermal growth factor derivative eye drop) is used to treat corneal epithelial defect, which can be caused in a variety of ways, including corneal mechanical injury, various corneal surgery treatments, mild dry eye with superficial punctate keratopathy, and minor chemical burns etc. Our patented formula with three additional amino acids at the amino terminal in the epidermal growth factor derivative substantially enhances its molecular stability, allowing the drug to be stored in room temperature.
Pinup® (Voriconazole), a broad-spectrum triazole anti-fungus drug used for treating invasive aspergillosis, severe invasive infections caused by fluconazole-resistant yeasts (including candida krusei), and severe infections caused by scedosporium species and fusarium species. The drug can be used to treat ongoing and possibly life-threating infections among immunosuppressive patients.
Mitiglinide is an insulintropic, glinide class drug used for treating type 2 diabetes. It has a fast onset of action, as well as a reduced risk of post-prandial hypoglycemia and dyslipidemia compared to other glinides in the market. These makes it suitable for elderlies, which account for 63% of the type 2 diabetic patients. The drug is currently sold under brand name Bokangtai® in China.
